G. Sulur
Theravance Biopharma (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lymphoma Diagnosis and Treatment, Prostate Cancer Treatment and Research, Immunotherapy and Immune Responses, Viral-associated cancers and disorders
Most-Cited Works
- → CXC and CC Chemokine Receptors on Coronary and Brain Endothelia(1999)130 cited
- → TCL1 Oncogene Expression in B Cell Subsets from Lymphoid Hyperplasia and Distinct Classes of B Cell Lymphoma(2001)96 cited
- → TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues(1999)78 cited
- → Epithelial membrane protein-2 is expressed in discrete anatomical regions of the eye(2003)49 cited
- → 1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study(2023)18 cited
- → 119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study(2023)10 cited
- → LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)(2018)5 cited
- → Benefit Of Abiraterone Acetate Plus Prednisone (AA+P) Added To Androgen Deprivation Therapy (ADT) In Patients With High-Risk, Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): Post Hoc Analysis Of EQ-5D-5L From The Latitude Study(2018)3 cited
- → Expression Pattern of Epithelial Membrane Protein 2 in Normal and Malignant Skin and Lung(2001)
- Restricted expression pattern of the putative tumor suppressor gene, Epithelial Membrane Protein 2 in the eye(2002)